Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

46.99
-13.5550-22.39%
Post-market: 47.050.0627+0.13%18:36 EDT
Volume:6.26M
Turnover:307.73M
Market Cap:1.60B
PE:-7.26
High:56.69
Open:55.41
Low:46.29
Close:60.55
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:28.53M
Volume Ratio:3.18
T/O Rate:21.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:1.78
PE(LYR):-4.83

Loading ...

Nektar selloff after rezpegaldesleukin data ‘unwarranted,’ says Jefferies

TIPRANKS
·
4 hours ago

William Blair says rezpeg data a positive for Nektar

TIPRANKS
·
6 hours ago

Nektar Therapeutics Down Nearly 21%, on Pace for Largest Percent Decrease Since February 2023

Dow Jones
·
6 hours ago

Nektar falls -21.6%

TIPRANKS
·
6 hours ago

Nektar Stock Sinks Despite Promising Hair Loss Treatment Data

Dow Jones
·
Yesterday

Nektar Says Phase 3 Zenith AD Trial for Rezpegaldesleukin Expands into Treatment-Experienced Patients

Reuters
·
Yesterday

Nektar Therapeutics - Rezpegaldesleukin Demonstrates Durability and Deepening of Response Through One Year of Treatment

THOMSON REUTERS
·
Yesterday

Nektar Therapeutics - Rezpegaldesleukin Safety Profile Through 52 Weeks Favorable and Consistent with Previous Reports

THOMSON REUTERS
·
Yesterday

Nektar Therapeutics - Phase 3 Zenith Aa Study to Initiate in Early 2027

THOMSON REUTERS
·
Yesterday

Nektar Therapeutics - Salt Score ≤20 Response Maintained in 75% at 4 Months, 63% at 6 Months Off Treatment

THOMSON REUTERS
·
Yesterday

Nektar Therapeutics Says Rezpegaldesleukin in Atopic Dermatitis Showed Improvements as Early as Week 2

MT Newswires Live
·
Yesterday

Nektar: Rezpegaldesleukin-associated improvements detected as early as Week 2

TIPRANKS
·
Sep 30

Nektar Says Rezpegaldesleukin Shows Early Biomarker Response in Phase 2b Rezolve-AD Atopic Dermatitis Study

Reuters
·
Sep 30

Nektar Says Phase 2b Rezolve-AA Trial Posts New 6-Month Off-Treatment Rezpegaldesleukin Data in Severe Alopecia Areata

Reuters
·
Sep 28

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (Eadv) Congress 2026

THOMSON REUTERS
·
Sep 28

Canaccord Genuity Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 28

Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG

Dow Jones
·
Sep 28

Nektar awarded $90M in Eli Lilly breach of contract case

TIPRANKS
·
Sep 28

Nektar selloff on trial brings ‘strong entry point,’ says BTIG

TIPRANKS
·
Sep 28

Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 26